Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acell, Artms, Medtronic, Products + Features, Quidel, Rapid Medical.
The U.S. FDA has granted emergency use authorization (EUA) for thousands of products for the COVID-19 pandemic, and the agency is legally required to advise companies of their post-pandemic options for new marketing authorization. Conversely, companies that fail to deal with inventory for expired EUAs may find themselves in the crosshairs of the FDA, whistleblowers, and federal and state attorneys, suggesting that manufacturers of devices should have a plan for dealing with unused inventories once the public health emergency comes to an end.
After nearly three months of the U.S. federal government operating on stopgap spending measures, Congress has agreed to a $1.4 trillion spending bill for fiscal 2021. The omnibus package, which includes $97 billion for the Department of Health and Human Services, gives both the FDA and NIH small increases in funding.
The latest global regulatory news, changes and updates affecting biopharma, including: USPTO to expand diversity in innovation; Opioid prescriptions could cost Walmart billions.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amgen, Appili, Biogen, Cytodyn, Dr. Reddy’s, Innovation, Kempharm, Nicox, Ocular, Onconova, Orchard, Polyphor, Takeda, Uniqure, Vertex, Ziopharm.
LONDON – The EMA has issued a positive opinion on Pfizer Inc./Biontech SE’s COVID-19 vaccine, BNT-162b2, becoming the first regulator to recommend a full marketing authorization, rather than approval for emergency use. The vaccine, now brand named Comirnaty, still has to go through the formality of being approved by EU member state governments, but the EU health commissioner, Stella Kyriakides, has said she expects roll out to start on Dec. 27.
The U.S. FDA has granted emergency use authorization (EUA) for thousands of products for the COVID-19 pandemic, and the agency is legally required to advise companies of their post-pandemic options for new marketing authorization. Conversely, companies that fail to deal with inventory for expired EUAs may find themselves in the crosshairs of the FDA, whistleblowers, and federal and state attorneys, suggesting that manufacturers of devices should have a plan for dealing with unused inventories once the public health emergency comes to an end.
CAJICA, Colombia – After a lengthy process, French spinal-cord implants manufacturer Implanet SA received marketing authorization by Cofepris, the Mexican health care surveillance agency, to distribute its Jazz platform in the Latin American country. Martillac, France-based Implanet is now looking to train surgeons in Mexico to use its Jazz platform that is designed to improve the treatment of spinal pathologies requiring vertebral fusion surgery.
RSS
